Matteo

Muna Therapeutics Initiates Phase 1 Trial with First Participants Dosed for Novel Oral TREM2 Agonist Targeting Early Alzheimer’s Disease Copenaghen (Denmark) – Golgi Neurosciences Srl is pleased to announce that its portfolio company Muna Therapeutics, a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has initiated a Phase 1 clinical study of its lead … Read more

Breye Therapeutics Reports Positive Phase 1b Results for Danegaptide, Supporting Progression to Phase 2 in Retinal Vascular Diseases Copenaghen (Denmark) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Danegaptide is a first-in-class, … Read more

Alcatraz Therapeutics being awarded “New Company with more transformative potential” at Bio-Neurosciences 2025 Amsterdam (The Netherlands) – We are excited to share that Stefan Lohmer, ad interim CEO of Alcatraz Therapeutics, recently presented the company at BioNeuroscience 2025 in Amsterdam. Alcatraz Therapeutics has been honored with the “New Company with more transformative potential” award! Currently … Read more

Libra Therapeutics Advances LBR-2950 Program securing a $5 Million MJFF grant. San Diego (CA, USA) – Libra Therapeutics Inc., a Golgi Neuroscience’s Portfolio company developing novel therapeutics to restore cellular balance and attenuate neurodegeneration, has secured a $5 Million grant to advance the LBR-2950 program from the The Michael J. Fox Foundation for Parkinson’s Research … Read more

Muna Therapeutics Announces Strategic Alliance with GSK to Advance Alzheimer’s Research Copenaghen (Denmark) – Muna Therapeutics ApS, a Golgi Neuroscience’s portfolio company developing therapies that slow or stop devastating neurodegenerative diseases, has achieved a major milestone by forming a strategic alliance with GSK. This multi-year collaboration aims to slow or halt the progression of Alzheimer’s … Read more

Lario Therapeutics Secures $6 Million MJFF Grant for Groundbreaking Parkinson’s Research Edinburgh (United Kingdom) – Lario Therapeutics Ltd, a preclinical stage biotech and Golgi Neurosciences’ portfolio company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders, has achieved a remarkable milestone by securing a $6 million grant from The Michael J. Fox Foundation … Read more

Acousia Therapeutics Launches PROHEAR-Study with First Patient Enrolled Tübingen (Germany) – Acousia Therapeutics GmbH, a Golgi Neurosciences’ portfolio company focused on hearing loss solutions, has achieved a significant milestone by enrolling the first patient in its PROHEAR-Study, a Phase 2a clinical trial. This study is set to explore the potential of ACOU085, a groundbreaking therapy … Read more

Breye Therapeutics to start Phase 1b/2a clinical trials Copenaghen (Denmark) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye Therapeutics has initiated phase 1b/2a clinical trial, with the scope to assess safety, … Read more